medi0618
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 29, 2019 (NCT04198558)
Timeline
Indications
Mechanism of action
- Proteinase-activated receptor 2INHIBITOR
F2RL1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06602479 | Phase 2 | Oct 7, 2024 | AstraZeneca |
| NCT05714254 | Phase 1 | Dec 12, 2022 | AstraZeneca |
| NCT04198558 | Phase 1 | Nov 29, 2019 | AstraZeneca, Humboldt University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 3 | 2 | 2019 |
| Humboldt University | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1